Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review
Abstract Background While data from several studies over the last decade has demonstrated that introduction of immunologic checkpoint blockage therapy with anti-CTLA-4/PD-1 drugs leads to improved survival in metastatic melanoma patients, relatively little is known about brain-specific therapeutic r...
Main Authors: | Marin A. McDonald, Parag Sanghvi, Julie Bykowski, Gregory A. Daniels |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4470-y |
Similar Items
-
Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients
by: Hélène Salaün, et al.
Published: (2022-12-01) -
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
by: Dahlia Fedele, et al.
Published: (2024-01-01) -
The age of enlightenment in melanoma immunotherapy
by: Mark R. Albertini
Published: (2018-08-01) -
Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases)
by: L. Yu. Vladimirova, et al.
Published: (2021-08-01) -
Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
by: Sadanori Furudate, et al.
Published: (2016-10-01)